Trial Profile
Phase 1 Study, Evaluating HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti HER2 small molecule imaging agent (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Diagnostic use
- 01 Oct 2020 Status changed from recruiting to discontinued.
- 20 May 2014 New trial record